510(k) K182702

SEKURE Creatine Kinase Assay by Sekisui Diagnostics P.E.I., Inc. — Product Code CGS

K182702 is an FDA 510(k) premarket notification submitted by Sekisui Diagnostics P.E.I., Inc. for the device "SEKURE Creatine Kinase Assay". The FDA issued a decision of Substantially Equivalent on Apr 17, 2019. The device falls under product code CGS (Nad Reduction/Nadh Oxidation, Cpk Or Isoenzymes), a Class II device regulated under 21 CFR 862.1215. Sekisui Diagnostics P.E.I., Inc. has 5 other 510(k) clearances on record.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Apr 17, 2019
Date Received
Sep 27, 2018
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
Nad Reduction/Nadh Oxidation, Cpk Or Isoenzymes
Device Class
Class II
Regulation Number
862.1215
Review Panel
CH
Submission Type
510(k)

Need the full FDA record for Sekisui Diagnostics P.E.I., Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K182702. Report a data issue: hello@regdatalab.com.